<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Ann Lab Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">Ann Lab Med</journal-id>
      <journal-id journal-id-type="publisher-id">ALM</journal-id>
      <journal-title-group>
        <journal-title>Annals of Laboratory Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2234-3806</issn>
      <issn pub-type="epub">2234-3814</issn>
      <publisher>
        <publisher-name>The Korean Society for Laboratory Medicine</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27834071</article-id>
      <article-id pub-id-type="pmc">5107623</article-id>
      <article-id pub-id-type="doi">10.3343/alm.2017.37.1.74</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter to the Editor</subject>
          <subj-group subj-group-type="subheading">
            <subject>Diagnostic Hematology</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Concurrence of e1a2 and e19a2 <italic>BCR-ABL1</italic> Fusion Transcripts in a Typical Case of Chronic Myeloid Leukemia</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>Jaehyeon</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Dal Sik</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>Hye Soo</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Choi</surname>
            <given-names>Sam Im</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Cho</surname>
            <given-names>Yong Gon</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>Department of Laboratory Medicine, Chonbuk National University Hospital, Jeonju, Korea.</aff>
      <aff id="A2"><label>2</label>Research Institute of Clinical Medicine of Chonbuk National University-Biomedical Research Institute of Chonbuk National University Hospital, Jeonju, Korea.</aff>
      <author-notes>
        <corresp>Corresponding author: Yong Gon Cho. Department of Laboratory Medicine, Chonbuk National University Medical School, Chonbuk National University Hospital, 20 Geonji-ro, Deokjin-gu, Jeonju 54907, Korea. Tel: +82-63-250-2388, Fax: +82-63-250-1200, <email>choyg@jbnu.ac.kr</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>01</day>
        <month>11</month>
        <year>2016</year>
      </pub-date>
      <volume>37</volume>
      <issue>1</issue>
      <fpage>74</fpage>
      <lpage>76</lpage>
      <history>
        <date date-type="received">
          <day>11</day>
          <month>2</month>
          <year>2016</year>
        </date>
        <date date-type="rev-recd">
          <day>30</day>
          <month>5</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>12</day>
          <month>9</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Korean Society for Laboratory Medicine.</copyright-statement>
        <copyright-year>2017</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
    </article-meta>
  </front>
  <body>
    <p>Dear Editor,</p>
    <p>There are three types of <italic>BCR-ABL1</italic> fusion transcripts that differ on the basis of the breakpoint in the <italic>BCR</italic> gene [<xref rid="B1" ref-type="bibr">1</xref>]. The major type, encoding p210, has two isoforms, b2a2 (e13a2) and b3a2 (e14a2), and is associated with more than 95% of Ph-positive CML cases. The minor type, encoding p190, is e1a2. The micro type, encoding p230, is e19a2. This micro type is rare, and has been associated with a variety of hematologic malignancies including neutrophilic CML (CML-N), all phases of classical CML, essential thrombocythemia (ET), and acute myeloid or lymphoblastic leukemia [<xref rid="B2" ref-type="bibr">2</xref><xref rid="B3" ref-type="bibr">3</xref>]. Here, we describe the first case of chronic phase CML concurrently expressing e1a2 and e19a2 <italic>BCR-ABL1</italic>.</p>
    <p>An 89-year-old woman was referred to our hospital for evaluation of her leukocytosis. She appeared ill, but had no splenomegaly. The complete blood count (CBC) revealed 137.46&#xD7;10<sup>9</sup>/L WBC, 10.0 g/dL Hb, and 194&#xD7;10<sup>9</sup>/L platelets. The blood smear demonstrated 3% blasts, basophilia, and eosinophilia, and bone marrow (BM) aspirate showed a hypercellularity (<xref ref-type="fig" rid="F1">Fig. 1</xref>). The karyotype in BM was 46,XX,t(9;22)(q34;q11.2) [20] and the FISH result using an LSI BCR/ABL probe (Abbott Molecular Inc., Des Plaines, IL, USA) was nuc ish (ABLx3),(BCRx3),(ABL con BCRx2)[200/200]. <italic>JAK2</italic> mutation was not detected.</p>
    <p>The commercial multiplex reverse transcription (RT)-PCR (HemaVision, DNA Diagnostic, Risskov, Denmark) result was positive for <italic>BCR/ABL</italic> in Master M6 and Split-out M6B PCR, and presented as an atypically thick band overlapping with the control band at 911 bp (<xref ref-type="fig" rid="F2">Fig. 2A</xref>). Additional sequencing from the M6B amplicon revealed the <italic>BCR-ABL1</italic> fusion was the micro type (e19a2) (<xref ref-type="fig" rid="F2">Fig. 2B</xref>). Another real-time quantitative PCR for the minor <italic>BCR-ABL1</italic> rearrangement indicated positivity (0.04, normalized copy number [NCN]), which was confirmed by sequencing (<xref ref-type="fig" rid="F2">Fig. 2C</xref>). Therefore, it was determined that the patient had a <italic>BCR-ABL1</italic> fusion consisting predominantly of the micro isoform (e19a2) with a small amount of the minor isoform (e1a2). The concurrence of those two isoforms might occur as a result of alternative splicing of the primary <italic>BCR-ABL1</italic> fusion transcript [<xref rid="B4" ref-type="bibr">4</xref>].</p>
    <p>The patient could not start any targeted therapy owing to her poor performance status and the potential interaction with her ongoing risperidone treatment. Only hydroxyurea (500 mg/day) was initiated. One month later, her WBC count decreased to 14.23&#xD7;10<sup>9</sup>/L. After 6 months, she showed no complications and her WBC count was 16.60&#xD7;10<sup>9</sup>/L.</p>
    <p>The e19a2 <italic>BCR-ABL1</italic> fusion transcript can be associated with three types of CML phenotypes, including CML-N, which is characterized by moderate and persistent neutrophilia, absent or minimal splenomegaly, and a benign clinical course [<xref rid="B2" ref-type="bibr">2</xref>]. Among typical CML, chronic phase CML presents with significant basophilia, marked splenomegaly, and elevation of circulating immature granulocytes [<xref rid="B5" ref-type="bibr">5</xref>]. Atypical CML with thrombocytosis (&gt;1,000&#xD7;10<sup>9</sup>/L) presents as low WBC count, high platelet count, and mild or absent splenomegaly, having a clinical course featuring ET [<xref rid="B6" ref-type="bibr">6</xref>]. The present case was a typical CML in the chronic phase, but lacked marked splenomegaly and monocytosis. The hyperleukocytosis (&gt;100&#xD7;10<sup>9</sup>/L) seen in this case is usually seen in more advanced, accelerated, or blast phases of CML. However, a case presenting in the chronic phase of CML with e19a2 was reported; the patient eventually worsened to blast crisis [<xref rid="B7" ref-type="bibr">7</xref>]. So, hyperleukocytosis could be an indicator of poor prognosis in chronic phases of CML carrying the e19a2 <italic>BCR-ABL1</italic> transcript.</p>
    <p>The e1a2 is present in 1-2% of typical CML in all phases, but especially in the chronic phase. Monocytosis is a typical feature of CML with e1a2, and is associated with a poor response to tyrosine kinase inhibitors [<xref rid="B8" ref-type="bibr">8</xref>]. In the present case, no monocytosis was observed, seemingly owing to the minimal expression of e1a2.</p>
    <p>Some reports have described the frequency of the concurrence of two <italic>BCR-ABL1</italic> isoforms. Small amounts of the p190 transcript have been observed and are attributed to alternative <italic>BCR</italic> splicing in more than 90% of patients with CML that predominantly express the p210 transcript [<xref rid="B9" ref-type="bibr">9</xref>]. So, the concurrence of two isoforms is not uncommon in CML patients. However, there have been no reports on the concurrence of p230 and p190 transcripts in CML patients.</p>
    <p>It is necessary to determine the incidence and clinical impact of the concurrence of p230 and p190 <italic>BCR-ABL1</italic> isoforms through further evaluation.</p>
  </body>
  <back>
    <ack>
      <title>Acknowledgments</title>
      <p>We thank DNA diagnostic A/S (Denmark) for assistance with the additional sequencing.</p>
    </ack>
    <fn-group>
      <fn fn-type="COI-statement">
        <p><bold>Authors' Disclosures of Potential Conflict of Interest:</bold> No conflicts of interest relevant to this article were reported.</p>
      </fn>
    </fn-group>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Melo</surname>
              <given-names>JV</given-names>
            </name>
          </person-group>
          <article-title>The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype</article-title>
          <source>Blood</source>
          <year>1996</year>
          <volume>88</volume>
          <fpage>2375</fpage>
          <lpage>2384</lpage>
          <pub-id pub-id-type="pmid">8839828</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pane</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Frigeri</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Sindona</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Luciano</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ferrara</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Cimino</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction)</article-title>
          <source>Blood</source>
          <year>1996</year>
          <volume>88</volume>
          <fpage>2410</fpage>
          <lpage>2414</lpage>
          <pub-id pub-id-type="pmid">8839830</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jeon</surname>
              <given-names>EK</given-names>
            </name>
            <name>
              <surname>Lim</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yahng</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Cho</surname>
              <given-names>BS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The first case of acute lymphoblastic leukemia with the e19a2 BCR-ABL1 transcript: imatinib therapy followed by unrelated donor transplantation induces a durable molecular response</article-title>
          <source>Leukemia</source>
          <year>2011</year>
          <volume>25</volume>
          <fpage>366</fpage>
          <lpage>367</lpage>
          <pub-id pub-id-type="pmid">21072049</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>van Rhee</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Hochhaus</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Melo</surname>
              <given-names>JV</given-names>
            </name>
            <name>
              <surname>Goldman</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Cross</surname>
              <given-names>NC</given-names>
            </name>
          </person-group>
          <article-title>p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias</article-title>
          <source>Blood</source>
          <year>1996</year>
          <volume>87</volume>
          <fpage>5213</fpage>
          <lpage>5217</lpage>
          <pub-id pub-id-type="pmid">8652835</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Briz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Vilches</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Cabrera</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>For&#xE9;s</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Fern&#xE1;ndez</surname>
              <given-names>MN</given-names>
            </name>
          </person-group>
          <article-title>Typical chronic myelogenous leukemia with e19a2 junction BCR/ABL transcript</article-title>
          <source>Blood</source>
          <year>1997</year>
          <volume>90</volume>
          <fpage>5024</fpage>
          <lpage>5025</lpage>
          <pub-id pub-id-type="pmid">9389724</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bertorelle</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bonaldi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bianchini</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ramazzina</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Del Mistro</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Zamboni</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The e19a2 BCR/ABL fusion transcript with additional chromosomal aberrations on a new case of chronic myeloid leukemia (CML) of mild type</article-title>
          <source>Leukemia</source>
          <year>2001</year>
          <volume>15</volume>
          <fpage>2003</fpage>
          <lpage>2004</lpage>
          <pub-id pub-id-type="pmid">11753631</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>How</surname>
              <given-names>GF</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>LT</given-names>
            </name>
            <name>
              <surname>Lim</surname>
              <given-names>LC</given-names>
            </name>
          </person-group>
          <article-title>Chronic myeloid leukemia with e19a2 (c3a2) BCR/ABL fusion junction--is it truly a benign disease?</article-title>
          <source>Leukemia</source>
          <year>1998</year>
          <volume>12</volume>
          <fpage>1166</fpage>
          <lpage>1167</lpage>
          <pub-id pub-id-type="pmid">9665206</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pardanani</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tefferi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Litzow</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Zent</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hogan</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>McClure</surname>
              <given-names>RF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Chronic myeloid leukemia with p190BCR-ABL: prevalence, morphology, tyrosine kinase inhibitor response, and kinase domain mutation analysis</article-title>
          <source>Blood</source>
          <year>2009</year>
          <volume>114</volume>
          <fpage>3502</fpage>
          <lpage>3503</lpage>
          <pub-id pub-id-type="pmid">19833856</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vardiman</surname>
              <given-names>JW</given-names>
            </name>
          </person-group>
          <article-title>Chronic myelogenous leukemia, BCR-ABL1+</article-title>
          <source>Am J Clin Pathol</source>
          <year>2009</year>
          <volume>132</volume>
          <fpage>250</fpage>
          <lpage>260</lpage>
          <pub-id pub-id-type="pmid">19605820</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" orientation="portrait" position="float">
      <label>Fig. 1</label>
      <caption>
        <title>Images of peripheral blood (A, 200&#xD7;) and bone marrow (B, 400&#xD7; and C, 200&#xD7;) showing typical morphology of CML in the chronic phase (A, B: Wright's stain, C: Hematoxylin &amp; Eosin stain). Bone marrow differential count showed 3.5% blasts, 1.5% promyelocytes, 12.5% myelocytes, 15.0% metamyelocytes, 18.5% band neutrophils, 35.5% segmented neutrophils, 5.0% eosinophils, 4.0% basophils, and 4.5% erythroblasts.</title>
      </caption>
      <graphic xlink:href="alm-37-74-g001"/>
    </fig>
    <fig id="F2" orientation="portrait" position="float">
      <label>Fig. 2</label>
      <caption>
        <title>Representative images of <italic>BCR-ABL1</italic> rearrangement in the present case. (A) Positive bands in commercial multiplex RT-PCR indicating e19a2: one (yellow arrowhead) is in Master M6 and Split-out M6B PCR, and presented as an atypically thick band overlapping with the control band at 911 bp; the other (white arrow) is in Master M8 and Split-out M8F. (B) Sequencing the M6B amplicon revealed the <italic>BCR-ABL1</italic> fusion as the micro type (e19a2). (C) Another sequencing result indicated positivity for e1a2, the minor <italic>BCR-ABL1</italic> rearrangement (0.04 normalized copy number [NCN]).</title>
      </caption>
      <graphic xlink:href="alm-37-74-g002"/>
    </fig>
  </floats-group>
</article>
</pmc-articleset>
